Meglumine antimoniate: Difference between revisions

Latest revision as of 03:47, 7 January 2014

Meglumine Antimoniate
GLUCANTIM^® WHO Prescribing Information
Description
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Dosage and Administration
How Supplied

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Meglumine antimonate

Overview

Meglumine antimoniate is a medicine used for treating leishmaniasis. It is manufactured by Aventis and sold as Glucantime in France, and Glucantim in Italy.

It belongs to a group of compounds known as the pentavalent antimonials. It is administered by intramuscular injection.

Brand Names

GLUCANTIM^®, GLUCANTIME^® (NOT AVAILABLE)

WHO Model Prescribing Information

Mechanism of Action

The mechanism of action of meglumine antimoniate is unknown, but may involve inhibition of the parasite's glycolytic and fatty acid oxidative activity resulting in decreased reducing equivalents for antioxidant defense and decreased synthesis of adenosine triphosphate.

References

@@ Line 1: / Line 1: @@
-{{drugbox
+__NOTOC__
-| IUPAC_name        =
+{{Meglumine antimoniate}}
-| image             = Meglumine antimoniate major component 3D.png
+{{CMG}}
-| CAS_number        = 133-51-7
-| ATC_prefix        = P01
-| ATC_suffix        = CB01
-| PubChem           = 64953
-| DrugBank          =
-| chemical_formula  = Variable
-| molecular_weight  = Variable
-| bioavailability   =
-| protein_bound     =
-| metabolism        =
-| elimination_half-life =
-| excretion         =
-| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
-| pregnancy_US      =  <!-- A / B            / C / D / X -->
-| pregnancy_category=
-| legal_AU          =  <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
-| legal_CA          =  <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
-| legal_UK          =  <!-- GSL         / P       / POM / CD / Class A, B, C -->
-| legal_US          =  <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
-| legal_status      =
-| routes_of_administration =
-}}
-'''Meglumine antimoniate''' (or '''meglumine antimonate''') is a medicine used for treating  [[leishmaniasis]].  It is manufactured by [[Aventis]] and sold as '''Glucantime''' in [[France]], and '''Glucantim''' in [[Italy]].  It belongs to a group of compounds known as the [[pentavalent antimonial]]s. It is administered by [[intramuscular injection]].
-{{Agents against leishmaniasis and trypanosomiasis}}
+{{SK}} Meglumine antimonate
-[[Category:Antiprotozoal agents]]
+==Overview==
-{{pharma-stub}}
+Meglumine antimoniate is a medicine used for treating  [[leishmaniasis]].  It is manufactured by [[Aventis]] and sold as '''Glucantime''' in France, and '''Glucantim''' in Italy.
-{{WikiDoc Sources}}
+It belongs to a group of compounds known as the [[pentavalent antimonial]]s. It is administered by [[intramuscular injection]].
+==Category==
+Antiparasitic
+==Brand Names==
+GLUCANTIM<sup>®</sup>, GLUCANTIME<sup>®</sup> (NOT AVAILABLE)
+==WHO Model Prescribing Information==
+'''  [[Meglumine antimoniate description|Description]]'''
+'''| [[Meglumine antimoniate indications and usage|Indications and Usage]]'''
+'''| [[Meglumine antimoniate contraindications|Contraindications]]'''
+'''| [[Meglumine antimoniate warnings and precautions|Warnings and Precautions]]'''
+'''| [[Meglumine antimoniate adverse reactions|Adverse Reactions]]'''
+'''| [[Meglumine antimoniate dosage and administration|Dosage and Administration]]'''
+'''| [[Meglumine antimoniate how supplied|How Supplied]]'''
+==Mechanism of Action==
+The mechanism of action of meglumine antimoniate is unknown, but may involve inhibition of the parasite's glycolytic and fatty acid oxidative activity resulting in decreased reducing equivalents for [[antioxidant]] defense and decreased synthesis of [[adenosine triphosphate]].
+==References==
+{{Reflist|2}}
+[[Category:Antibiotics]]
+[[Category:Wikinfect]]